Posted On: 10/28/2015 11:59:07 PM
Post# of 72446
Re: lousy.engineer #15172
Totally agree. CTIX has 3 drugs in human trials for 4 different indications. AVXL's success depends on its drug platform proving efficacious for something -- Alzheimer's, seizures, or Parkinson's -- but it carries much more risk because it's basically one drug platform, not 3 completely different drugs like CTIX has.
I can't understand how such a small company as CTIX can possibly have such a rich pipeline. Quite amazing.
From the comments some people make, you'd think none of CTIX's drugs are worth anything, when in fact any one of them succeeding could match the PCYC, ACAD, and JAZZ stories, and having multiple drugs succeed could make those amazing stories look sick.
I still plan to hold AVXL at least through the upcoming news, and probably much longer -- but I have more confidence in CTIX in the long run.
I can't understand how such a small company as CTIX can possibly have such a rich pipeline. Quite amazing.
From the comments some people make, you'd think none of CTIX's drugs are worth anything, when in fact any one of them succeeding could match the PCYC, ACAD, and JAZZ stories, and having multiple drugs succeed could make those amazing stories look sick.
I still plan to hold AVXL at least through the upcoming news, and probably much longer -- but I have more confidence in CTIX in the long run.
(0)
(0)
